We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Gene Associated With Familial High Cholesterol

By LabMedica International staff writers
Posted on 26 May 2016
Print article
Image: Clinical manifestation of Homozygous Familial Hypercholesterolemia, interdigital xanthoma (Photo courtesy of the National Organization for Rare Disorders).
Image: Clinical manifestation of Homozygous Familial Hypercholesterolemia, interdigital xanthoma (Photo courtesy of the National Organization for Rare Disorders).
The gene that explains one quarter of all familial hypercholesterolemia with very high blood cholesterol has been revealed. Familial hypercholesterolemia is the most common genetic disorder leading to premature death, found in 1 in 200 people.

The reason why lipoprotein(a) concentrations are raised in individuals with clinical familial hypercholesterolemia is unclear. The hypotheses that high lipoprotein(a) cholesterol and LPA risk genotypes are a possible cause of clinical familial hypercholesterolemia, and that individuals with both high lipoprotein(a) concentrations and clinical familial hypercholesterolemia have the highest risk of myocardial infarction.

Scientists at the Copenhagen University Hospital (Herlev, Denmark) carried out a prospective cohort study that included data from 46,200 individuals from the Copenhagen General Population Study who had lipoprotein(a) measurements and were genotyped for common familial hypercholesterolemia mutations. Individuals receiving cholesterol-lowering drugs had their concentrations of Low-density lipoprotein (LDL) and total cholesterol multiplied by 1·43, corresponding to an estimated 30% reduction in LDL cholesterol from the treatment. In lipoprotein(a) cholesterol-adjusted analyses, total cholesterol and LDL cholesterol were adjusted for the lipoprotein(a) cholesterol content by subtracting 30% of the individuals' lipoprotein(a) total mass before total and LDL cholesterol were used for diagnosis of clinical familial hypercholesterolemia.

The team used unadjusted LDL cholesterol, mean lipoprotein(a) concentrations were 23 mg/dL in individuals unlikely to have familial hypercholesterolemia, 32 mg/dL in those with possible familial hypercholesterolemia, and 35 mg/dL in those with probable or definite familial hypercholesterolemia. When adjusting LDL cholesterol for lipoprotein(a) cholesterol content the corresponding values were 24 mg/dL for individuals unlikely to have familial hypercholesterolemia, 22 mg/dL for those with possible familial hypercholesterolemia, and 21 mg/dL for those with probable or definite familial hypercholesterolemia. High lipoprotein(a) cholesterol accounted for a quarter of all individuals diagnosed with clinical familial hypercholesterolemia and LPA risk genotypes were more frequent in clinical familial hypercholesterolemia, whereas lipoprotein(a) concentrations were similar in those with and without familial hypercholesterolemia mutations.

Borge G. Nordestgaard, MD, a professor and the senior author of the study, said, “Our results suggest that all individuals with familial hypercholesterolemia should have their lipoprotein(a) concentrations measured in order to identify those with the highest concentrations and therefore also the highest risk of suffering a heart attack. Our findings will help identify the individuals with the highest risk of suffering a heart attack and hopefully facilitate better preventive treatment for these extremely high risk individuals.” The study was published on May 12, 2016, in the journal The Lancet Diabetes & Endocrinology.

Related Links:
Copenhagen University Hospital

Gold Member
Hematology Analyzer
Swelab Lumi
Automated Blood Typing System
IH-500 NEXT
New
Auto-Chemistry Analyzer
CS-1200
New
Human Insulin CLIA
Human Insulin CLIA Kit

Print article

Channels

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.